Pharmaceutical Industry
Filter News
Found 43,682 articles
-
Early data from the Phase III TALAPRO-2 study showed Talzenna, Pfizer’s oral PARP inhibitor, met its primary endpoint in metastatic castration-resistant prostate cancer patients.
-
Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock - October 04, 2022
10/4/2022
Rocket Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 6,800,000 shares of its common stock at a public offering price of $14.75 per share.
-
Bionomics Limited to Participate in the Cantor Neurology & Psychiatry Conference
10/4/2022
Bionomics Limited announced that it will be participating in the Cantor Neurology & Psychiatry Conference to be held at The Ritz-Carlton in San Francisco on October 6-7, 2022.
-
Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron
10/4/2022
Immuron Limited is pleased to announce that it has executed a Master Service Agreement with US-based Pharmaron CPC, Inc. a Maryland Corporation located in Baltimore USA.
-
Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct Reprogramming
10/4/2022
Astellas Pharma Inc. and Pantherna Therapeutics GmbH announced that the companies have entered into a new technology evaluation agreement for research to generate mRNA-based regenerative medicine programs using direct reprogramming.
-
Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial
10/4/2022
Pfizer Inc. announced positive topline results from the Phase 3 TALAPRO-2 study of TALZENNA®, an oral poly ADP-ribose polymerase inhibitor, in combination with XTANDI® compared to placebo plus XTANDI in men with metastatic castration-resistant prostate cancer, with or without homologous recombination repair gene mutations.
-
KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary Angioedema
10/4/2022
KalVista Pharmaceuticals, Inc. announced that it has terminated the KOMPLETE phase 2 clinical trial for KVD824 for the prevention of attacks in people with hereditary angioedema.
-
ChromaDex Shares Promising Findings from Clinical Study Showcasing the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction
10/4/2022
ChromaDex Corp. announced promising findings from a clinical study, as reported in the peer-reviewed journal Journal of the American College of Cardiology : Basic to Translational Science by a team of scientists led by Dr. Kevin O’Brien, Division of Cardiology, Department of Medicine, in collaboration with Dr. Rong Tian, Mitochondria and Metabolism Center, Department of Anesthesiology and Pain Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
-
Immunic to Participate in Scientific and Industry Conferences in October 2022
10/4/2022
Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced participation in the following scientific and industry conferences in October:
-
Poolbeg Pharma PLC Announces POLB 001 US Patent update
10/4/2022
Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, provides an update on the strengthening of its intellectual property position around POLB 001, a small molecule immunomodulator for the treatment of severe influenza.
-
Saol Therapeutics Announces Enrollment Achievement in Pivotal Phase 3 Trial for Rare Mitochondrial Disease - Pyruvate Dehydrogenase Complex Deficiency (PDCD)
10/4/2022
Saol Therapeutics announced that the pivotal Phase 3 clinical trial evaluating Sodium Dichloroacetate for the treatment of a rare, pediatric, ultra-orphan mitochondrial disease, Pyruvate Dehydrogenase Complex Deficiency has achieved its targeted enrollment.
-
Data presented at the International Bladder Cancer Network (IBCN) meeting demonstrate a reduction in the risk of recurrence with the use of BLC
10/4/2022
Photocure ASA announces the presentation of clinical data and its breakout session in the scientific program at the International Bladder Cancer Network Meeting held September 29th-October 2nd in Barcelona, Spain.
-
Hemostemix Announces Exploring Clinical Trial Financing Alternatives
10/4/2022
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that the Company has commenced discussions with pharmaceutical companies to explore potential clinical trial financing alternatives for its lead product ACP-01 (the "Clinical Trial Financing Alternatives")
-
Plus Therapeutics to Share Data in Oral Presentations from Ongoing ReSPECT™ Clinical Trials at the 35th Annual Congress of the European Association of Nuclear Medicine
10/4/2022
Plus Therapeutics, Inc. today announced it will present data from two ongoing clinical trials evaluating the Company’s lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome ( 186 RNL), in recurrent glioblastoma and leptomeningeal metastases at the 35th Annual Congress of the European Association of Nuclear Medicine (EANM), being held October 15-19, 2022 in Barcelona, Spain.
-
AstraZeneca is acquiring LogicBio Therapeutics in a deal worth $68 million. The deal bolsters AstraZeneca’s efforts to braoden its portfolio in genomics and rare diseases.
-
Clene’s gold nanocrystal asset CNM-Au8 failed to hit the primary endpoint in the HEALEY ALS trial, but strong survival signals at six months warrant additional exploration in treating ALS.
-
Myovant Sciences formed a special committee of independent directors to assess Sumitovant Biopharma's offer after Sumitovant announced plans to acquire the company.
-
Intercept Pharmaceuticals' Ocaliva failed to treat patients with compensated cirrhosis due to nonalcoholic steatohepatitis better than a placebo in a Phase III trial, the company announced Friday.
-
Incyte Corporation will acquire privately-held Villaris and AmplifyBio will acquire PACT Pharma, while Estrella will gain a spot on the Nasdaq Exchange.
-
The third quarter of 2022 saw continued job cuts, a shift in focus away from COVID-19, an unexpected boost in the Alzheimer’s research space and increased scrutiny of accelerated approvals.